Harvard Bioscience Inc - Asset Resilience Ratio

Latest as of September 2018: 0.00%

Harvard Bioscience Inc (HBIO) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Harvard Bioscience Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$0.00
Cash + Short-term Investments

Total Assets

$165.04 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2017)

This chart shows how Harvard Bioscience Inc's Asset Resilience Ratio has changed over time. See Harvard Bioscience Inc (HBIO) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Harvard Bioscience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Harvard Bioscience Inc (HBIO) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $0.00 0%
Total Liquid Assets $0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Harvard Bioscience Inc maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Harvard Bioscience Inc Industry Peers by Asset Resilience Ratio

Compare Harvard Bioscience Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Andon Health Co Ltd
SHE:002432
Medical Instruments & Supplies 18.11%
AVE Science & Technology Co Ltd
SHG:688067
Medical Instruments & Supplies 24.13%
Ansell Ltd
AU:ANN
Medical Instruments & Supplies 7.53%
Nanosonics Ltd
AU:NAN
Medical Instruments & Supplies 46.84%
SDI Ltd
AU:SDI
Medical Instruments & Supplies 3.36%
Austco Healthcare Ltd
AU:AHC
Medical Instruments & Supplies 15.90%
Trajan Group Holdings Ltd
AU:TRJ
Medical Instruments & Supplies 0.29%
Osteopore Ltd
AU:OSX
Medical Instruments & Supplies 22.60%

Annual Asset Resilience Ratio for Harvard Bioscience Inc (2011–2017)

The table below shows the annual Asset Resilience Ratio data for Harvard Bioscience Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2017-12-31 0.00% $0.00 $109.35 Million --
2016-12-31 0.00% $0.00 $107.77 Million --
2015-12-31 0.00% $0.00 $120.22 Million --
2014-12-31 0.00% $0.00 $135.92 Million --
2013-12-31 0.00% $0.00 $135.46 Million --
2012-12-31 0.00% $0.00 $133.48 Million --
2011-12-31 0.00% $0.00 $126.63 Million --
pp = percentage points

About Harvard Bioscience Inc

NASDAQ:HBIO USA Medical Instruments & Supplies
Market Cap
$27.06 Million
Market Cap Rank
#24164 Global
#5137 in USA
Share Price
$6.00
Change (1 day)
+0.84%
52-Week Range
$0.38 - $7.24
All Time High
$8.47
About

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrop… Read more